The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Analyst Price Targets
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Apple's Multi-Year iPhone Upgrade Cycle and AI Features To Drive Upside, Analysts Say
DraftKings Reports Q2 Miss, Analysts Wonder If Surcharges On Winnings Are A 'Gamble'
Apple's Multi-Year iPhone Upgrade Cycle and AI Features To Drive Upside, Analysts Say
DraftKings Reports Q2 Miss, Analysts Wonder If Surcharges On Winnings Are A 'Gamble'
10 Amazon Analysts Assess Q2 Earnings: Strong AWS Growth, Retail Challenges
Apple Analyst Warns Investors About Betting Against Tech Giant As iPhone Maker On Cusp Of AI-Driven Supercycle: 'Flex The Muscles Moment For Cook & Co'
10 Amazon Analysts Assess Q2 Earnings: Strong AWS Growth, Retail Challenges
Apple Analyst Warns Investors About Betting Against Tech Giant As iPhone Maker On Cusp Of AI-Driven Supercycle: 'Flex The Muscles Moment For Cook & Co'
Mastercard Outperforms Visa In Q2; Analysts Highlight Defensive Edge In Spending Volatility
Meta Platforms 'In Rarified Air' With Scale, Growth, Profitability: 12 Analysts Size Up Q2 Results, How 'Zuck Won AI Bingo Before The Game Started'
Read More...
Price Target Recent News
Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from Pfizer and GSK.
Block Inc. Earns Analyst Praise: Q2 Results Showcase Cash App Growth, Strategic Innovations
Block reports a beat and raise quarter. Analysts look forward to details of the company's go-to-market strategy.
Lululemon Downgraded: Goldman Analyst Flags Competitive Pressures, Weak Innovation, Lower Traffic
Goldman Sachs downgraded Lululemon to Neutral, citing declining store traffic, weak innovation, and rising promotional activity.
LabCorp Analysts Boost Their Forecasts After Better-Than-Expected Earnings
Shake Shack Analysts Increase Their Forecasts After Upbeat Sales
These Analysts Cut Their Forecasts On Cognex Following Q2 Results
DoorDash Analysts Boost Their Forecasts After Strong Sales
These Analysts Revise Their Forecasts On Atlassian After Q4 Results
These Analysts Cut Their Forecasts On Snap After Weak Sales
Microchip Technology Analysts Slash Their Forecasts After Q1 Results
Apple To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Friday
Apple Stock Nearly Holds Up Despite Magnificent 7 Sell-Off In Premarket: What's Going On
Apple analysts have talked up its quarterly results and have expressed confidence in the way forward for the company.
Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 7% Dividend Yields
Chevron Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Exxon Mobil Likely To Report Higher Q2 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts